Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Azorin, J.-M. Articles by Bourdeix, I. Search for Related Content PubMed Citation Articles by Azorin, J.-M. Articles by Bourdeix, I. Schizophrenia Spectrum Disorders Other Neuroleptics

A Double-Blind Comparative Study of Clozapine and Risperidone in the Management of Severe Chronic Schizophrenia

OBJECTIVE: This prospective, double-blind, multicenter, parallel-group study compared the efficacy and safety of therapeutic doses of clozapine and risperidone in patients with severe chronic schizophrenia and poor previous treatment response. METHOD: Male or female patients aged 18–65 years who met DSM-IV criteria for schizophrenia and study requirements for poor previous treatment response (N=273) were randomly assigned to double-blind treatment with either clozapine or risperidone administered over 12 weeks in increasing increments. The primary efficacy measures were the magnitude of improvement in Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) scores. Adverse events were recorded throughout the study. RESULTS: The magnitude of improvement in mean BPRS and CGI scores from baseline to end of the study was significantly greater in the clozapine group than in the risperidone group. Statistically significant differences in favor of clozapine were also seen for most of the secondary efficacy measures (Positive and Negative Syndrome Scale, Calgary Depression Scale, Psychotic Depression Scale, and Psychotic Anxiety Scale). The adverse event profile was similar for both treatment groups, with a lower risk of extrapyramidal symptoms in the clozapine group. CONCLUSIONS: Clozapine showed superior efficacy over risperidone in this patient population. Both treatments were equally well tolerated as demonstrated through their adverse event profiles, although as expected clozapine was associated with a lower risk of extrapyramidal symptoms than risperidone.

This article has been cited by other articles:

				J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features Schizophr Bull, July 1, 2009; 35(4): 775 - 788. [Abstract] [Full Text] [PDF]

				S. Leucht, K. Komossa, C. Rummel-Kluge, C. Corves, H. Hunger, F. Schmid, C. Asenjo Lobos, S. Schwarz, and J. M. Davis A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia Am J Psychiatry, February 1, 2009; 166(2): 152 - 163. [Abstract] [Full Text] [PDF]

				S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics Am J Psychiatry, February 1, 2006; 163(2): 185 - 194. [Abstract] [Full Text] [PDF]

				J. Tauscher, T. Hussain, O. Agid, N. P. L.G. Verhoeff, A. A. Wilson, S. Houle, G. Remington, R. B. Zipursky, and S. Kapur Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics Am J Psychiatry, September 1, 2004; 161(9): 1620 - 1625. [Abstract] [Full Text] [PDF]

				S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al. Physical Health Monitoring of Patients With Schizophrenia Am J Psychiatry, August 1, 2004; 161(8): 1334 - 1349. [Abstract] [Full Text] [PDF]

				J. M. Davis, N. Chen, and I. D. Glick A Meta-analysis of the Efficacy of Second-Generation Antipsychotics Arch Gen Psychiatry, June 1, 2003; 60(6): 553 - 564. [Abstract] [Full Text] [PDF]

				D. N. OSSER and A. AKHTER Comparative Effectiveness of Antipsychotic Drugs Am J Psychiatry, March 1, 2003; 160(3): 590 - 590. [Full Text]

				Other Articles Noted Evid. Based Ment. Health, May 1, 2002; 5(2): 40 - 40. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us